Al Hammadi Holding Company announces the increase of capital of one of its affiliate in Kingdom of Saudi Arabia
| Element List | Explanation |
|---|---|
| Announcement Detail | The Extraordinary General Assembly of Sudair Pharmaceuticals Company, a closed joint-stock company (one of the affiliate companies of Al-Hammadi Holding and owned at a 35% stake), approved on Monday 08/01/2024 the increase in the capital of Sudair Pharmaceuticals Company from 57 million Saudi Riyals to 173 million Saudi Riyals, with an increase of 116 million Saudi Riyals. This increase in capital will be carried out through a transfer of the partners' current balance according to each partner's capital share.
It's worth mentioning that the purpose behind the capital increase is to support the financial position of the affiliate company, as well as to foster the growth and development of its business operations. Please note that the capital increase is contingent upon regulatory approvals. |
Comments